Hepatitis A virus strain HM175 antigen (formaldehyde inactivated)
Listing at source
Listed
Drug name
Hepatitis A virus strain HM175 antigen (formaldehyde inactivated)
gsk biologicals 2 dose inactivated hepatitis a vaccine havrix
GSK Biologicals 2-dose inactivated hepatitis A vaccine (Havrix)
havrix
Havrix
HAVRIX
Havrix (HAV)
Havrix (investigational formulation)
havrix hav
havrix healive
havrix investigational formulation
Havrix®
Havrix™
HAVRIX™
healive havrix
FDA ingredient codes (UNII)
5BFC8LZ6LQ
Related records
Trials (49)
A Phase I Randomized, Observer-Blinded, Dose-Ranging Study in Healthy Subjects 24 to <72 Months of Age
A Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine in Children
A Study to Evaluate the Safety and Immunogenicity of a Prime-boost Schedule of GSK Biologicals' Influenza Vaccine in Children
A Study to Evaluate the Safety and Immunogenicity of the Hepatitis A Virus Vaccine HAVpur in Healthy Young Children
A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years
An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children
Antibody Persistence & Immune Memory in Healthy Adults Previously Vaccinated With Twinrix Adult
Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given as Booster or a 2 Dose Catch up Schedule
Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate Vaccine
COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine
Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067)
Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440
Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age
Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B Vacc
Effectiveness of Booster With 1 or 2 Doses of HAV Vaccine Among HIV-infected Patients
Effects of Aging on Primary and Secondary Vaccine Responses
Efficacy and Durability of Hepatitis A Vaccination in Patients With Advanced Fibrosis and Cirrhosis
Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease
Evaluation of Immune Memory to Twinrix or Comparator by Challenge Dose Administration 4 Years After Primary Vaccination
Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)